MEPs share concerns about COVID-19 variants | Nieuws | Europees Parlement

 

MEPs share concerns about COVID-19 variants 

Persbericht 
 
 
MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

Background

All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

 
  • Direct naar de inhoud van de pagina (druk op "Enter")
  • Direct naar de inhoud van de pagina (druk op "Enter")Direct naar de inhoud van de pagina (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar talenmenu (druk op "Enter")Rechtstreeks naar talenmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")
  • Rechtstreeks naar zoekmenu (druk op "Enter")Rechtstreeks naar zoekmenu (druk op "Enter")
  • BG - български
  • BG - български BG - българскиBG - български
  • ES - español
  • ES - español ES - españolES - español
  • CS - čeština
  • CS - čeština CS - češtinaCS - čeština
  • DA - dansk
  • DA - dansk DA - danskDA - dansk
  • DE - Deutsch
  • DE - Deutsch DE - DeutschDE - Deutsch
  • ET - eesti keel
  • ET - eesti keel ET - eesti keelET - eesti keel
  • EL - ελληνικά
  • EL - ελληνικά EL - ελληνικάEL - ελληνικά
  • EN - English
  • EN - English EN - EnglishEN - English
  • FR - français
  • FR - français FR - françaisFR - français
  • GA - Gaeilge
  • GA - Gaeilge GA - GaeilgeGA - Gaeilge
  • HR - hrvatski
  • HR - hrvatski HR - hrvatskiHR - hrvatski
  • IT - italiano
  • IT - italiano IT - italianoIT - italiano
  • LV - latviešu valoda
  • LV - latviešu valoda LV - latviešu valodaLV - latviešu valoda
  • LT - lietuvių kalba
  • LT - lietuvių kalba LT - lietuvių kalbaLT - lietuvių kalba
  • HU - magyar
  • HU - magyar HU - magyarHU - magyar
  • MT - Malti
  • MT - Malti MT - MaltiMT - Malti
  • NL - Nederlands
  • NL - Nederlands NL - NederlandsNL - Nederlands
  • PL - polski
  • PL - polski PL - polskiPL - polski
  • PT - português
  • PT - português PT - portuguêsPT - português
  • RO - română
  • RO - română RO - românăRO - română
  • SK - slovenčina
  • SK - slovenčina SK - slovenčinaSK - slovenčina
  • SL - slovenščina
  • SL - slovenščina SL - slovenščinaSL - slovenščina
  • FI - suomi
  • FI - suomi FI - suomiFI - suomi
  • SV - svenska
  • SV - svenska SV - svenskaSV - svenska
  • Naar pagina gaan Nieuws
  • Naar pagina gaan Nieuws Naar pagina gaan Nieuws Naar pagina gaanNieuws
  • Naar pagina gaan Leden
  • Naar pagina gaan Leden Naar pagina gaan Leden Naar pagina gaanLeden
  • Naar pagina gaan Over het Parlement
  • Naar pagina gaan Over het Parlement Naar pagina gaan Over het Parlement Naar pagina gaanOver het Parlement
  • Naar pagina gaan Plenaire vergadering
  • Naar pagina gaan Plenaire vergadering Naar pagina gaan Plenaire vergadering Naar pagina gaanPlenaire vergadering
  • Naar pagina gaan Commissies
  • Naar pagina gaan Commissies Naar pagina gaan Commissies Naar pagina gaanCommissies
  • Naar pagina gaan Delegaties
  • Naar pagina gaan Delegaties Naar pagina gaan Delegaties Naar pagina gaanDelegaties
  • Andere websites Andere websites
  • Naar pagina gaan Multimedia Centre
  • Naar pagina gaan Multimedia Centre Naar pagina gaan Multimedia Centre Naar pagina gaanMultimedia Centre
  • Naar pagina gaan Webpagina van de Voorzitter
  • Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaan Webpagina van de Voorzitter Naar pagina gaanWebpagina van de Voorzitter
  • Naar pagina gaan Secretariaat-generaal
  • Naar pagina gaan Secretariaat-generaal Naar pagina gaan Secretariaat-generaal Naar pagina gaanSecretariaat-generaal
  • Naar pagina gaan Think tank
  • Naar pagina gaan Think tank Naar pagina gaan Think tank Naar pagina gaanThink tank
  • Naar pagina gaan EP Newshub
  • Naar pagina gaan EP Newshub Naar pagina gaan EP Newshub Naar pagina gaanEP Newshub
  • Naar pagina gaan Tot uw dienst
  • Naar pagina gaan Tot uw dienst Naar pagina gaan Tot uw dienst Naar pagina gaanTot uw dienst
  • Naar pagina gaan Bezoeken
  • Naar pagina gaan Bezoeken Naar pagina gaan Bezoeken Naar pagina gaanBezoeken
  • Naar pagina gaan Legislative train
  • Naar pagina gaan Legislative train Naar pagina gaan Legislative train Naar pagina gaanLegislative train
  • Naar pagina gaan Contracten en subsidies
  • Naar pagina gaan Contracten en subsidies Naar pagina gaan Contracten en subsidies Naar pagina gaanContracten en subsidies
  • Naar pagina gaan Registreren
  • Naar pagina gaan Registreren Naar pagina gaan Registreren Naar pagina gaanRegistreren
    Nieuws Europees Parlement NieuwsNieuws Europees Parlement Europees Parlement Menu Menu
  • Nieuws
  • Nieuws Nieuws Nieuws
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Europese zaken
  • Naar pagina gaan Europese zaken Naar pagina gaan Europese zaken Naar pagina gaanEuropese zaken
  • Naar pagina gaan Wereld
  • Naar pagina gaan Wereld Naar pagina gaan Wereld Naar pagina gaanWereld
  • Naar pagina gaan Economie
  • Naar pagina gaan Economie Naar pagina gaan Economie Naar pagina gaanEconomie
  • Naar pagina gaan Maatschappij
  • Naar pagina gaan Maatschappij Naar pagina gaan Maatschappij Naar pagina gaanMaatschappij
  • Naar pagina gaan Veiligheid
  • Naar pagina gaan Veiligheid Naar pagina gaan Veiligheid Naar pagina gaanVeiligheid
  • Pers
  • Pers Pers Pers
  • Naar pagina gaan Startpagina
  • Naar pagina gaan Startpagina Naar pagina gaan Startpagina Naar pagina gaanStartpagina
  • Naar pagina gaan Accreditatie
  • Naar pagina gaan Accreditatie Naar pagina gaan Accreditatie Naar pagina gaanAccreditatie
  • Naar pagina gaan Contact
  • Naar pagina gaan Contact Naar pagina gaan Contact Naar pagina gaanContact
  • Agenda
  • Agenda Agenda Agenda
  • Naar pagina gaan Hoogtepunten
  • Naar pagina gaan Hoogtepunten Naar pagina gaan Hoogtepunten Naar pagina gaanHoogtepunten
  • Naar pagina gaan Wekelijkse agenda
  • Naar pagina gaan Wekelijkse agenda Naar pagina gaan Wekelijkse agenda Naar pagina gaanWekelijkse agenda
  • Naar pagina gaan Briefing
  • Naar pagina gaan Briefing Naar pagina gaan Briefing Naar pagina gaanBriefing
  • Veelgestelde vragen
  • Veelgestelde vragen Veelgestelde vragen Veelgestelde vragen
  • #EuropeanenTegenCovid19
  • #EuropeanenTegenCovid19 #EuropeanenTegenCovid19 #EuropeanenTegenCovid19Naar het zoekveld
    Zoekopdracht starten Europees Parlement
    Pers   > Huidige pagina: MEPs share concerns about COVID-19 variants  
    Pers   > Pers  Pers > Huidige pagina: MEPs share concerns about COVID-19 variants   Huidige pagina: MEPs share concerns about COVID-19 variants   Huidige pagina:MEPs share concerns about COVID-19 variants  Pers  Pers >
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     
     
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

     
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     
     
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     

    MEPs share concerns about COVID-19 variants 

    Persbericht 
     

    MEPs share concerns about COVID-19 variants 

    MEPs share concerns about COVID-19 variants 
    MEPs share concerns about COVID-19 variants 
    Persbericht 
     
    Persbericht 
    Persbericht  ENVI  ENVIENVI 
     
     
     
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

     
     
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

     
     
     

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp 
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
     MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE        
     MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE        
     MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE    
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE  
    MEPs share concerns about efficacy of vaccines against COVID-19 variants ©AFP/Valery HACHE 

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    On Monday, Members of the Environment, Public Health and Food Safety Committee debated with experts on the efficacy of vaccines against mutations of the COVID-19 virus.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    Representatives from the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO) updated MEPs on the state of play of existing COVID-19 variants. They shared information regarding how effective authorised vaccines are against different variants, and discussed global challenges and the need for a global coordinated response to addressing variants.

    European Medicines AgencyEuropean Centre for Disease Prevention and ControlWorld Health Organisation

    MEPs expressed their concerns regarding fast-spreading variants, especially given the vaccination rate across the EU remains lower than expected. They lamented the lack of data available on the efficacy of administered vaccines. Certain member states have a low or no capacity to analyse virus samples (“genomic sequencing”), many MEPs said, which means the spread of variants and their impact cannot be adequately monitored. Members also quizzed the experts on the authorisation process for updated vaccines, on the role of vaccination certificates, and on the safety and side effects of existing vaccines.

    During the meeting, Commission Deputy Director-General for Health Pierre Delsaux presented the Commission’s communication on the HERA Incubator, a project designed to monitor variants, exchange data and cooperate on adapting vaccines. The Commission has proposed to amend the current regulatory procedure in order to allow for COVID-19 vaccines that are adapted to new variants to be approved more quickly.

    HERA Incubator

    You can watch the recording of the debate here and the video statement of Committee Chair, Pascal Canfin (Renew, FR) here.

    herehere

    Background

    Background

    All viruses – including SARS-CoV-2, the virus that causes COVID-19 – evolve over time. These changes are called “mutations”. A virus with one or more new mutations is referred to as a “variant” of the original virus. The ECDC’s latest risk assessment states that variants are more easily transmitted and more severe. Existing licensed COVID-19 vaccines may therefore be only partially effective or significantly less effective against a variant. For this reason, the risk associated with further spread of COVID-19 is currently assessed as “high to very high”.

    risk assessment

    According to the WHO, COVID-19 vaccines currently being developed or already approved are expected to provide at least some protection against new variants of the virus. In the event that any of these vaccines prove to be less effective against one or more variants, the composition of the vaccines can be adapted to protect against these variants.

    WHO

    Contact: 

    Contact: 
    Contact: 
  • Dana POPP 

    Dana POPP Dana POPP 
    Press Officer 
    Press Officer Press Officer 
    Contactgegevens: 
    Contactgegevens: 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) 
  • Telefoonnummer: (+32) 2 28 46330 (BXL) Telefoonnummer: (+32) 2 28 46330 (BXL)Telefoonnummer: (BXL) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) 
  • Telefoonnummer: (+33) 3 881 74903 (STR) Telefoonnummer: (+33) 3 881 74903 (STR)Telefoonnummer: (STR) 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 
  • Mobiel telefoonnummer: (+32) 470 95 17 07 Mobiel telefoonnummer: (+32) 470 95 17 07Mobiel telefoonnummer:  
  • E-mail: dana.popp@europarl.europa.eu 
  • E-mail: dana.popp@europarl.europa.eu E-mail: dana.popp@europarl.europa.euE-mail:  
  • E-mail: envi-press@europarl.europa.eu 
  • E-mail: envi-press@europarl.europa.eu E-mail: envi-press@europarl.europa.euE-mail:  
  • Twitteraccount: @EP_Environment 
  • Twitteraccount: @EP_Environment Twitteraccount: @EP_EnvironmentTwitteraccount:  
     
     

    Further information 

    Further information 
    Further information 
  • Video statement by ENVI Chair, Pascal Canfin (Renew, FR) (15.03.2021)  Video statement by ENVI Chair, Pascal Canfin (Renew, FR) (15.03.2021) 
  • Experts’ presentations (15.03.2021)  Experts’ presentations (15.03.2021) 
  • Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 (EMA reflection paper) (25.02.2021)  Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 (EMA reflection paper) (25.02.2021) 
  • Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers (EMA) (25.02.2021)  Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers (EMA) (25.02.2021) 
  • Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update (ECDC) (15.02.2021)  Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update (ECDC) (15.02.2021) 
  • Infographic: Mutation of SARS-CoV2 - current variants of concern (ECDC) (8.02.2021)  Infographic: Mutation of SARS-CoV2 - current variants of concern (ECDC) (8.02.2021) 
  • The effects of virus variants on COVID-19 vaccines (WHO) (1.03.2021)  The effects of virus variants on COVID-19 vaccines (WHO) (1.03.2021) 
  • Coronavirus: preparing Europe for the increased threat of variants (HERA Incubator - European Commission) (17.02.2021)  Coronavirus: preparing Europe for the increased threat of variants (HERA Incubator - European Commission) (17.02.2021) 
  • Free photos, video and audio material related to EU vaccines strategy   Free photos, video and audio material related to EU vaccines strategy  
     
     
     
     
     

    Productinformatie 

    REF.:  20210311IPR99707 

    Productinformatie 

    Productinformatie 
    Productinformatie 
    Productinformatie 
    REF.:  20210311IPR99707 
    REF.:  20210311IPR99707 
    REF.: REF.:REF.: 20210311IPR99707 20210311IPR99707 

    Deel deze pagina: 

    Deel deze pagina: 
    Deel deze pagina: 
  • Facebook Facebook 
  • Twitter Twitter 
  • LinkedIn LinkedIn 
  • Whatsapp Whatsapp Aanmelden voor e-mailupdatesAanmelden voor e-mailupdatesPdf-versie Pdf-versie 

    Voettekst 

    Voettekst Nieuws  Bekijk het menu: nieuws  Bekijk het menu: nieuws 
    Het Parlement in uw land 
  • Brussels  
  • Brussels   Brussels 
  • Den Haag  
  • Den Haag   Den Haag Tools 
  • Wetgevingsobservatorium  
  • Wetgevingsobservatorium   Wetgevingsobservatorium 
  • Multimedia Centre  
  • Multimedia Centre   Multimedia Centre 
  • EbS  
  • EbS   EbS 
    De Voorzitter van het Europees Parlement 
  • Webpagina van de Voorzitter van het Parlement  
  • Webpagina van de Voorzitter van het Parlement   Webpagina van de Voorzitter van het Parlement  Menu verbergen: Nieuws   Menu verbergen: Nieuws Europees Parlement  Menu bekijken: Europees Parlement   Menu bekijken: Europees Parlement 
  • Nieuws 
  • Nieuws  Nieuws 
  • Leden 
  • Leden  Leden 
  • Over het Parlement 
  • Over het Parlement  Over het Parlement 
  • Plenaire vergadering 
  • Plenaire vergadering  Plenaire vergadering 
  • Commissies 
  • Commissies  Commissies 
  • Delegaties 
  • Delegaties  Delegaties Menu verbergen: Europees Parlement Menu verbergen: Europees Parlement  

    Het Parlement in de sociale media  

    Het Parlement in de sociale media 
  • Facebook  
  • Facebook   Facebook 
  • Twitter  
  • Twitter   Twitter 
  • Facebook  
  • Facebook   Facebook 
  • LinkedIn  
  • LinkedIn   LinkedIn 
  • YouTube  
  • YouTube   YouTube 
  • Instagram  
  • Instagram   Instagram 
  • Pinterest  
  • Pinterest   Pinterest 
  • Snapchat  
  • Snapchat   Snapchat 
  • Reddit  
  • Reddit   Reddit Informatieve links 
  • Contact 
  • Contact Contact 
  • RSS 
  • RSS RSS 
  • Sitemap 
  • Sitemap Sitemap 
  • Juridische mededeling 
  • Juridische mededeling Juridische mededeling 
  • Privacybeleid 
  • Privacybeleid Privacybeleid 
  • Toegankelijkheid 
  • Toegankelijkheid Toegankelijkheid